Navigation Links
Aeterna Zentaris Reports First Quarter 2010 Financial and Operating Results
Date:5/13/2010

--------------------------------------------- $ $ Cash and cash equivalents 26,947 38,100 Accounts receivable and other current assets 10,383 10,913 Restricted cash 833 878 Property, plant and equipment 3,885 4,358 Other long-term assets 29,924 32,013 ------------------------------------------------------------------------- Total assets 71,972 86,262 ------------------------------------------------------------------------- ------------------------------------------------------------------------- Accounts payable and other current liabilities 14,777 19,211 Current portion of long-term payable 59 57 Long-term payable 118 143 Non-financial long-term liabilities* 53,848 57,625 ------------------------------------------------------------------------- Total liabilities 68,802 77,036 Shareholders' equity 3,170 9,226 ------------------------------------------------------------------------- Total liabilities and shareholders' equity 71,972 86,262 ------------------------------------------------------------------------- ------------------------------------------------------------------------- * Comprised mainly of deferred revenues and employee future benefits.


'/>"/>
SOURCE AETERNA ZENTARIS INC.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Aeterna Zentaris: FDA Approves Investigational New Drug (IND) Application for Doxorubicin Targeted Conjugate Compound, AEZS-108, in Bladder Cancer
2. Aeterna Zentaris Receives Orphan-Drug Designation from the FDA for AEZS-108 in Ovarian Cancer
3. AEterna Zentaris Announces Termination of Agreement with sanofi-aventis U.S. for the Development, Commercialization and Licensing of Cetrorelix in Benign Prostatic Hyperplasia
4. AEterna Zentaris Partner, Keryx, Initiates Phase 3 Registration Trial with Perifosine (KRX-0401) for the Treatment of Patients with Advanced Multiple Myeloma
5. AEterna Zentaris Announces Appointment of New Board Member
6. AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology
7. AEterna Zentaris Announces Results from its European Phase 3 Study with Cetrorelix in Benign Prostatic Hyperplasia
8. AEterna Zentaris Anti-Cancer Compound, Perifosine (KRX-0401), Receives FDA Fast Track Designation for the Treatment of Relapsed/Refractory Multiple Myeloma
9. AEterna Zentaris Announces Positive Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Endometrial Cancer
10. AEterna Zentaris Receives US$5.5 Million from Institutional Investors
11. AEterna Zentaris to Raise US$5.5 Million from Institutional Investors at US$1.20 Per Share
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... ... 28, 2015 , ... Since the initial launch of FireflySci Inc. (FFS) in early 2015, the ... service. Images such as the Fonz in a lab coat and Large Marge have ... humdrum spectroscopy field. , FireflySci is proud to be the only cuvette manufacturer ...
(Date:8/27/2015)... , Aug. 27, 2015  Neogen Corporation (NASDAQ: ... the stock of United Kingdom -based ... microbiological culture media and diagnostic systems. ... into a leading provider of microbial testing and diagnostic ... testing markets. The company currently sells into more than ...
(Date:8/27/2015)... , Aug. 27, 2015  Asterias Biotherapeutics, Inc. ... emerging field of regenerative medicine, today announced that executives ... in the month of September.  , ... at Rodman & Renshaw,s 17th Annual Global Investment Conference ... at the St. Regis Hotel in New ...
(Date:8/27/2015)... YORK , August 27, 2015 ... enhancing image processing functions in the human vision system, announced ... point guard Chris Paul to develop ... players who want to improve their real-life on-court performance. ... the court, whether it is shooting a ball or blocking ...
Breaking Biology Technology:Cuvette Manufacturer FireflySci Launches Back to School Deals with Complimentary Shipping On All Orders 2Neogen acquires U.K.-based Lab M Holdings 2Asterias Biotherapeutics to Present at Upcoming Investor Conferences 2Eight-Time All-Star Chris Paul and GlassesOff Partner to Develop Innovative Mobile App Designed to Improve On-Court Performance 2Eight-Time All-Star Chris Paul and GlassesOff Partner to Develop Innovative Mobile App Designed to Improve On-Court Performance 3
... Alfacell Corporation,(Nasdaq: ACEL ) today reported its financial ... 31, 2008., The company recorded a net loss ... common share, for the fourth fiscal quarter ended,July 31, ... or $0.05 per,basic and diluted common share, for the ...
... Oct. 14 /Xinhua-PRNewswire-FirstCall/ -- China Sky One,Medical, Inc. ... CSKI ), a,leading fully integrated pharmaceutical company ... ("PRC"), announced today that it,started production at Peng ... that it acquired, on October 14, 2008., ...
... and facilitate new R&D,collaborations-, WASHINGTON, Oct. 14 ... that the Bill & Melinda Gates Foundation has,expanded ... further engage,biotechnology industry innovation to create new medicines ... million grant will help BVGH build,the market case ...
Cached Biology Technology:Alfacell Reports Fiscal Fourth Quarter and Full Year 2008 Financial Results 2Alfacell Reports Fiscal Fourth Quarter and Full Year 2008 Financial Results 3Alfacell Reports Fiscal Fourth Quarter and Full Year 2008 Financial Results 4Alfacell Reports Fiscal Fourth Quarter and Full Year 2008 Financial Results 5China Sky One Medical, Inc. Starts Production at Newly Acquired Facility and Reaffirms Guidance 2China Sky One Medical, Inc. Starts Production at Newly Acquired Facility and Reaffirms Guidance 3BIO Ventures for Global Health Receives $7 Million Grant from Gates Foundation to Engage Biotechnology in the Fight Against Neglected Diseases of the Developing World 2
(Date:8/3/2015)... , Aug. 3, 2015 Synaptics, Inc. ... interface solutions, today announced that members of the executive ... the Pacific Crest Global Technology Leadership Forum on Tuesday, ... conference will be held at the Sonnenalp Resort in ... The presentation may include forward-looking information. An audio webcast ...
(Date:7/31/2015)... , Chine, 31 juillet 2015 La ... www.icg-10.org ) sera organisée par le BGI du ... Shenzhen en Chine. La ... son inauguration en 2006, l,ICG est devenue l,une ... le domaine des « omiques » et c,est aussi la ...
(Date:7/31/2015)... 31, 2015 The 10 th International Conference ... BGI from October 22-25, 2015, in Shenzhen , ... is celebrating its 10 th anniversary this year. Since its ... most influential annual meetings in the ,omics, fields, and is ... ICG-10 focuses on recent breakthroughs and advances ...
Breaking Biology News(10 mins):La 10e International Conference on Genomics (ICG-10) doit s'ouvrir en octobre 2La 10e International Conference on Genomics (ICG-10) doit s'ouvrir en octobre 3The 10th International Conference on Genomics (ICG-10) to Open in October 2
... N.Y. (Tuesday, April 1, 2008) Identifying genes ... the mouse used to be a monumental task. ... it effective for even the smallest laboratories. This ... ( www.cshprotocols.org/TOCs/toc4_08.dtl ) highlights a method for screening the ...
... Challenges and Promise of Cell-Based Therapies is ... medicine using stem cells. The opening plenary session will ... will be followed by four plenary sessions that will ... musculoskeletal, and metabolic diseases and disorders. It will close ...
... 2008Biotechnology companies are focusing on the development of ... diagnostic tests for cancer, reports Genetic Engineering and ... forward, a much stronger and targeted emphasis on ... in the April 1 issue of GEN ( ...
Cached Biology News:Cold Spring Harbor Protocols features methods to screen genomes and analyze evolution 2Challenges and promise of cell-based therapies 2
...
LabFax: Immunochemistry...
Mycoplasma Removal Agent (MRA) has been developed for cell culture, to combat the widespread problems caused by contamination of cell cultures with mycoplasma....
Request Info...
Biology Products: